CARLSBAD, Calif., Nov. 6, 2015 /PRNewswire/ -- Isis
Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense
therapeutics, today announced that management will present a
company overview at the following investor conferences:
- 24th Annual Credit Suisse Healthcare Conference on
Wednesday, November 11, 2015 in
Scottsdale, AZ;
- 2015 Stifel Healthcare Conference on Wednesday, November 18, 2015 in New York, NY; and
- 27th Annual Piper Jaffray Healthcare Conference on
Tuesday, December 1, 2015 in
New York, NY.
The above listed dates are subject to change. Details on
presentation times or changes to presentation dates can be found on
the Company's website. Please check www.isispharm.com for the
latest information.
A live webcast of the presentations will be available on the
"Investors & Media" section of the Isis website. The
replays will be available within 48 hours and will be archived for
a limited time.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is the leading
company in RNA-targeted drug discovery and development focused on
developing drugs for patients who have the highest unmet medical
needs, such as those patients with severe and rare
diseases. Using its proprietary antisense technology, Isis has
created a large pipeline of first-in-class or best-in-class drugs,
with over a dozen drugs in mid- to late-stage development.
Drugs currently in Phase 3 development include volanesorsen, a drug
Isis is developing and plans to commercialize through its wholly
owned subsidiary, Akcea Therapeutics, to treat patients with
familial chylomicronemia syndrome and familial partial
lipodystrophy; ISIS-TTRRx, a drug Isis is developing
with GSK to treat patients with all forms of TTR amyloidosis; and
ISIS-SMNRx, a drug Isis is developing with Biogen to
treat infants and children with spinal muscular atrophy. Isis'
patents provide strong and extensive protection for its drugs and
technology. Additional information about Isis is available at
www.isispharm.com.
ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This
press release includes forward-looking statements regarding Isis
Pharmaceuticals' financial position and outlook, Isis' business,
and the therapeutic and commercial potential of Isis' technologies
and products, including volanesorsen,
ISIS-SMNRx and ISIS-TTRRx, in
development. Any statement describing Isis' goals,
expectations, financial or other projections, intentions or beliefs
is a forward-looking statement and should be considered an at-risk
statement. Such statements are subject to certain risks and
uncertainties, particularly those inherent in the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics, and in the endeavor of
building a business around such drugs. Isis' forward-looking
statements also involve assumptions that, if they never materialize
or prove correct, could cause its results to differ materially from
those expressed or implied by such forward-looking statements.
Although Isis' forward-looking statements reflect the good
faith judgment of its management, these statements are based only
on facts and factors currently known by Isis. As a result,
you are cautioned not to rely on these forward-looking
statements. These and other risks concerning Isis' programs
are described in additional detail in Isis' annual report on Form
10-K for the year ended December 31,
2014, and its most recent quarterly report on Form 10-Q,
which are on file with the SEC. Copies of these and other
documents are available from the Company.
Isis Pharmaceuticals® is a registered trademark of
Isis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark
of Isis Pharmaceuticals, Inc.
Logo -
http://photos.prnewswire.com/prnh/20130807/LA60006LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/isis-pharmaceuticals-to-present-at-upcoming-investor-conferences-300173714.html
SOURCE Isis Pharmaceuticals, Inc.